Streetbeat News

Price Targets

RCL

Mizuho analyst Ben Chaiken initiates coverage on Royal Caribbean Gr (NYSE:RCL) with a Buy rating and a price target of $164.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:59 am

GPI

Guggenheim analyst Ronald Jewsikow upgrades Group 1 Automotive (GPI) from Neutral to Buy with a $305 price target, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:56 am

AR

Morgan Stanley analyst Devin McDermott upgraded Antero Resources (NYSE:AR) from Equal-Weight to Overweight and increased the price target from $26 to $36.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:56 am

AEON

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on AEON Biopharma (AMEX:AEON) with a maintained price target of $18.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:50 am

CLNN

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Clene (NASDAQ:CLNN) and maintained a $7 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:42 am

CNTB

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Connect Biopharma Holdings (CNTB) and raises the price target from $7 to $8.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:40 am

JBHT

B of A Securities analyst Ken Hoexter maintains a Buy rating on JB Hunt Transport Services (JBHT) but lowers the price target from $215 to $199.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:38 am

PGR

B of A Securities analyst Joshua Shanker maintains a Buy rating on Progressive (NYSE:PGR) but lowers the price target from $279 to $273.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:37 am

WDC

B of A Securities analyst Wamsi Mohan maintains a Buy rating on Western Digital (NASDAQ:WDC) and raises the price target from $75 to $85, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:35 am

JNJ

B of A Securities analyst Geoff Meacham maintains a Neutral rating on Johnson & Johnson (JNJ) and lowers the price target from $180 to $170.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:33 am